4.3 Article

Bile Acid Sequestrants for Lipid and Glucose Control

期刊

CURRENT DIABETES REPORTS
卷 10, 期 1, 页码 70-77

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-009-0087-5

关键词

Bile acid receptor; Bile acid sequestrant; Cholesterol; Glucose control; Lipid control; Type 2 diabetes mellitus

资金

  1. Daiichi Sankyo, Inc
  2. GlaxoSmithKline
  3. Novo Nordisk
  4. Takeda Pharmaceuticals
  5. Medtronic
  6. Merck
  7. Xoma
  8. Tethys
  9. Bristol-Myers Squibb
  10. AstraZeneca
  11. Pfizer
  12. sanofi-aventis
  13. Eli Lilly
  14. US National Institutes of Health
  15. American Diabetes Association

向作者/读者索取更多资源

Bile acids are generated in the liver and are traditionally recognized for their regulatory role in multiple metabolic processes including bile acid homeostasis, nutrient absorption, and cholesterol homeostasis. Recently, bile acids emerged as signaling molecules that, as ligands for the bile acid receptors farnesoid X receptor (FXR) and TGR5, activate and integrate multiple complex signaling pathways involved in lipid and glucose metabolism. Bile acid sequestrants are pharmacologic molecules that bind to bile acids in the intestine resulting in the interruption of bile acid homeostasis and, consequently, reduction in low-density lipoprotein cholesterol levels in hypercholesterolemia. Bile acid sequestrants also reduce glucose levels and improve glycemic control in persons with type 2 diabetes mellitus (T2DM). This article examines the mechanisms by which bile acid-mediated activation of FXR and TGR5 signaling pathways regulate lipid and glucose metabolism and the potential implications for bile acid sequestrant-mediated regulation of lipid and glucose levels in T2DM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据